Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives Final approval from the USFDA for Micafungin for Injection26-10-2022
26-10-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Ketorolac Tromethamine Tablets22-10-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
1. Zydus receives tentative approval from the USFDA for Valbenazine Capsules and 2. Zydus receives tentative approval from the USFDA for Roflumilast Tablets17-10-2022
Jhunjhunwala's firm Rare in talks with Barclays to prepay Rs 500 crore loan
The loan was used to fund the acquisition of Zydus Cadila's animal healthcare business in 202110-10-2022
Zydus Lifesciences Ltd - 532321 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliance Certificate06-10-2022
Zydus Lifesciences Ltd - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of Share Certificate06-10-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from USFDA and 180 days shared exclusivity for Brivaracetam Tablets06-10-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives tentative approval from the USFDA for Amantadine Extended-Release Capsules04-10-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from USFDA and 180 days shared exclusivity for Mirabegron Extended-Release Tablets 3.10.2203-10-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Sildenafil for Oral Suspension01-10-2022